Cancer Clinical Trials

Interior Content

Participating in a clinical trial can be a life-changing experience. When you join a clinical trial, you not only take an active role in fighting your own cancer, but you also help researchers and scientists develop new medications and treatments to help other cancer patients live longer.

 

At The Christ Hospital Health Network, we are recognized as a national leader in clinical research and for best practice standards in patient care. Our research and innovation has led to breakthrough medical advances and improved outcomes for nearly 40 years.

 

Every day, our doctors and researchers work to find cures for cancer - but we don't do it alone. Our patients play an essential role in finding better ways to prevent, diagnose and treat cancer.

 

Promising new therapies for cancer

Our clinical trials are conducted at various locations including:

  • The Christ Hospital Cancer Center

  • The Christ Hospital Physicians - Hematology & Oncology

  • The Christ Hospital Physicians - Surgical Oncology

  • Other clinical sites throughout Greater Cincinnati

We average 15 active studies, from phase I though phase IV. Phases are steps that clinical trials go through. If a new treatment is successful in one phase, it moves on to testing in the next phase.

 

Search our clinical trials

Find a clinical trial that is right for you. Below is a categorized list (alphabetical by cancer type) of all of our studies updated monthly so you know you're getting the latest information available. All of the following trials are currently recruiting. To refer a patient or enroll in a currently recruiting cancer cohort, call a research nurse at the Lindner Research Center at 513-585-1777.

  • Breast Cancer

  • Colon & Rectal Cancer

  • Head & Neck Cancer

  • Lung Cancer

  • Large B-Cell Lymphoma

  • Melanoma & Skin Cancer

  • Prostate Cancer

  • Renal Cell Cancer

All Newly Diagnosed, Untreated Cancer Patients

The Circulating Cell-free Genome Atlas Study (CCGA)- Identifier—NCT02889978

GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.


Breast Cancer

Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER)Identifier--NCT02953340

The purpose of this study is to compare the efficacy of SPI-2012 with pegfilgrastim in patients with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) to prevent and reduce Neutropenia that is associated with cancer chemotherapy.


Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1)Identifier-- NCT03078751

This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk breast cancer.


S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

This randomized, phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer. It compares whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR)-positive, and human epidermal growth factor receptor (HER)2-negative breast cancer.

 

NCT01901094 Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection.

 

A211102 Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer

The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (early cell changes that are thought to be a marker of breast cancer risk) in women at increased risk for breast cancer. There will be testing for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. The study will compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better.

 

Note: The standard drug used for the "breast cancer prevention" is tamoxifen. If the patient is eligible to take tamoxifen, he/she must be offered tamoxifen prevention as part of clinical care. Metformin and tamoxifen are not similar and function differently. This study is not investigating the use of tamoxifen. Metformin is not approved for preventing breast cancer, but is currently being tested to determine if it can prevent breast cancer.

 

Study to Assessthe Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozolefor the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

The purpose of this Phase IIIb study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer.

Colon & Rectal Cancer

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)

The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 and Phase 2.

Head & Neck Cancers

Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaIdentifier-- NCT02521870

This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD 101 injections in combination with intravenous pembrolizumab in patients with metastatic melanoma or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).


Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)

This is a phase 1a/b single-arm, open-label study to evaluate safety, tolerability, PK, and clinical benefit of FPA008 in combination with nivolumab in patients with selected advanced cancers.

Lung Cancer

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

This phase III, open-label, randomized study is designed to investigate the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) compared with best supportive care following adjuvant Cisplatin-based chemotherapy in PD-L1-selected patients with completely resected stage IB-IIIA non-small cell lung cancer.

 

Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003) - PD-1 naïve pts ONLY

This is a phase 1a/b single-arm, open-label study to evaluate safety, tolerability, PK, and clinical benefit of FPA008 in combination with nivolumab in patients with selected advanced cancers.

 

A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)

The purpose of this study is to determine the safety and effectiveness of nivolumab and ipilimumab compared to chemotherapy in the treatment of early stage non-small cell lung cancer.

 

Noninvasive (cell-free [cf]DNA) vs. Invasive (biopsy-based tumor sequencing) Lung Evaluation (NILE-Trial) in Metastatic Untreated Non-Small Cell Lung Cancer (NSCLC-non-squamous)

This trial will explore whether cfDNA testing from peripheral blood samples is non-inferior to tissue tumor genotyping in detecting NCCN-recommended biomarkers in first-line, treatment-naïve, metastatic non-squamous NSCLC.

Melanoma & Skin Cancer

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and bevacizumab, block tumor growth in different ways by targeting certain cells.
 

Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma

Phase 1b Subjects will be treated with talimogene laherparepvec until all injectable tumors have disappeared, disease progression per modified Immune-Related Response Criteria (irRC), or intolerance of study treatment, up to a maximum of 24 months of study treatment. Subjects will be treated with MK-3475 (pembrolizumab) until complete response (CR) disease progression per irRC, or intolerance of study treatment, up to a maximum of 24 months of study treatment. In Phase 3, Subjects will be treated with talimogene laherparepvec plus pembrolizumab(arm 1) or placebo plus pembrolizumab (arm 2) until 24 months from the date of the first dose of pembrolizumab or end of treatment due to disappearance of injectable lesions, complete response, disease progression per irRC-RECIST or intolerance of study treatment.

 

A Trial of IntratumoralInjections of SD-101in Combination With Pembrolizumab in Patients With Metastatic Melanoma

This is a Phase 1b/2 open-label trial to assess the safety, tolerability, biologic-activity, and preliminary efficacy of intratumoral SD-101 injections in combination with intravenous pembrolizumab in patients with advance or metastatic melanoma.

Renal Cell Cancer

Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)

This is a phase 1a/b single-arm, open-label study to evaluate safety, tolerability, PK, and clinical benefit of FPA008 in combination with nivolumab in patients with selected advanced cancers.